Supplementary Data from <i>TP53, STK11</i>, and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

Abstract

<p>Figures S1-12 Tables S1-S4 Supplementary material Supplementary Table S1. Antibodies used in flow cytometry experiments. Supplementary Table S2. Baseline characteristics of the 221 patients with lung adenocarcinoma in each TIP. Supplementary Table S3. Univariate Cox proportional-hazard analyses for progression-free survival and overall survival according to the mutational status of tumors in nivolumab treated patients. Supplementary Table S4. Baseline characteristics of the 32 patients with advanced-stages lung adenocarcinoma treated by nivolumab according to the mutational status of their tumor. Supplementary Figure S1. Spearman-correlation matrix of immune cell densities. Supplementary Figure S2. Comparison of immune cell densities, overall survival, molecular alteration frequency, and PD-L1 expression by tumor cells, between patients from TIP-1a and 1b. Supplementary Figure S3. TP53, STK11 and EGFR mutations strongly impact lung adenocarcinoma immune profiles. Supplementary Figure S4. Patterns of TP53, EGFR and STK11 mutations in the three TIPs. Supplementary Figure S5. No impact of KRAS mutations on the immune composition of TP53-Mut/STK11-EGFR-WT tumors and of TP53-STK11-EGFR-WT tumors. Supplementary Figure S6. Flow cytometry gating strategy used to characterize CD8 T cells from freshly resected tumors of lung adenocarcinoma patients. Supplementary Figure S7. Effector functions of CD8 TILs in TP53-Mut/STK11-EGFR-WT tumors vs TP53-WT tumors. Supplementary Figure S8. Higher MHC-I expression by malignant cells in TP53-Mut/ STK11- EGFR-WT tumors and its impact on tumor immune profiles. Supplementary Figure S9. Impact on the survival of nivolumab treated patients of TP53, KRAS, STK11 and EGFR mutations. Supplementary Figure S10. Anti-PD-1 efficacy in advanced-stage NSCLC patients according to distinct combinations of TP53, EGFR and STK11 mutations. Supplementary Figure S11. Impact of KRAS mutations on anti-PD-1 efficacy in advanced-stage NSCLC patients with TP53-Mut/STK11-EGFR-WT, TP53-STK11-EGFR-WT and in STK11-Mut/TP53-EGFR-WT tumors. Supplementary Figure S12. Impact of PD-L1 expression on the PFS of patients treated by anti-PD-1 according to distinct combinations of TP53, EGFR and STK11 mutations.</p>